OLR1 and diabetic kidney disease: Intravenous administration of anti-LOX-1 Ab has been widely used to target LOX-1, leading to reductions in inflammation, oxidative stress, and leukocyte infiltration in response to endotoxin-mediated lung injury, diabetic nephropathy, and vascular injury (22–24).